Our mission is to provide state-of the-art care to children and adults with type 1 diabetes and to teach our patients how to prevent or delay complications. Our research is devoted to finding prevention, cure, and most effective treatment of diabetes and associated disorders.
Marian Rewers, MD, PhD
The Barbara Davis Center for Diabetes (BDC) specializes in type 1 diabetes research and care for children and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus (map) in Aurora, Colorado. The Center was funded by Marvin Davis, in 1978, and is generously supported by the Children’s Diabetes Foundation (CDF).
clinical researchers, and basic biomedical scientists work at the BDC to
find the most effective treatment, prevention, and cure for type 1
diabetes. The Center provides state-of-the-art diabetes care to 3600
children and 2400 adults with diabetes from the Rocky Mountain Region as
well as receiving national and international referrals. We also provide
inpatient care to patients who are seen at the Children’s Hospital
Colorado with any type of diabetes.
The Center’s faculty teach the medical,
physician assistant, nursing, and dental students on campus. Residents
and endocrinology fellows train at the Center on elective rotations.
Basic science faculty members provide mentorship to pre-doctoral
students and post-doctoral fellows from around the world.
Childhood Diabetes Prevention
Screening for T1D
Shore Family Auditorium,
Nighthorse Campbell Native Health Building
University of Colorado Anschutz
8-3:15, November 15, 2019
Type 1 diabetes (T1D) affects 1.3 million
people in the U.S. The incidence continues to increase 3-5% annually. Clinical
diagnosis is preceded by months or years of pre-symptomatic autoimmunity to
pancreatic beta cells. Once multiple islet autoantibodies are present in
children, they inevitably progress to diabetes.
The JDRF, the American Diabetes Association, and the Endocrine Society
have recognized that T1D should be diagnosed when a child develops multiple
islet autoantibodies (stage 1) irreversibly leading to dysglycemia (stage 2)
and symptomatic hyperglycemia (stage 3 T1D). Symptoms of diabetes are often
overlooked by parents and providers.
The objectives of this symposium are:
1) To discuss novel approaches in the prevention of T1D
2) To summarize current analyses of
cost-effectiveness in the screening and prevention of T1D
3) To explore the role
of genetic markers in the prediction of T1D
Agiostratidou, Director, Helmsley Charitable Trust T1D Program
Jesse Bushman Senior Director of Health Policy, JDRF
Daniels, Chair, Department of Pediatrics, UC AMC
Dunne, Director, JDRF Research Cure/Prevention
Hagopian, Pacific Northwest Diabetes Research Institute
Thomas Hoerger & Carolina Barbosa, RTI International/CDC
Jeffrey Krischer, Director, Health Informatics Institute, University of South Florida
Francisco Leon & Leni Ramos, Provention Bio
Edwin Liu, Arleta Rewers & Marisa Stahl, Department of Pediatrics, UC AMC
Brett McQuinn, School of Pharmacy, UC AMC
Stephen Rich, Director, Center for Public Health Genomics, University of Virginia
Matt Sussman & Jennifer Benner, Boston Health Economics
Brigitte Frohnert, Andrea Steck, Todd Alonso, and Marian Rewers, Barbara Davis Center for Diabetes